Research
Hormonal
Insulin resistance is a primary driver of cardiovascular disease in Type 2 Diabetes, often outweighing the direct impact of hyperglycemia on coronary heart disease risk.
For Type 2 Diabetes, managing insulin resistance (through lifestyle, weight management, and specific medications) is likely more critical for preventing heart attacks than focusing solely on lowering blood sugar levels.
GoodQualifiesHIGH confidence
In type 2 diabetes classic risk factors and insulin resistance are more important risk factors for CVD than hyperglycemia.
Why this rating
Supported by prospective population studies, meta-analyses, and mathematical modeling (Archimedes model) showing prevention of insulin resistance prevents significant MI rates.
Source
Cardiovascular Disease in Type 2 Diabetes From Population to Man to Mechanisms
Markku Laakso · Diabetes Care · 2010
DOI 10.2337/dc09-0749
narrative_reviewCited 304×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Type 2 diabetes acts as a coronary heart disease (CHD) equivalent, conferring a risk of myocardial infarction in diabetic patients without prior history that is equal to or greater than that of nondiabetic patients with prior myocardial infarction.Good
- Pre-diabetes (Impaired Fasting Glucose and Impaired Glucose Tolerance) is associated with a twofold higher risk of cardiovascular events compared to normoglycemic subjects, driven by insulin resistance and clustering of risk factors.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →